Malaria: Difference between revisions
From WikiDemocracy
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 151: | Line 151: | ||
[https://www.nature.com/articles/s41541-020-00259-3 by David C. Kaslow 20/11/20 npj] | [https://www.nature.com/articles/s41541-020-00259-3 by David C. Kaslow 20/11/20 npj] | ||
This collection of malaria vaccine research and innovation papers highlights the intersection of efforts to: (1) achieve the pan-African1 and global goal2 of “Zero Malaria”; and (2) make the compelling case for immunization3 as a set of new tools for malaria control and elimination. | This collection of malaria vaccine research and innovation papers highlights the intersection of efforts to: (1) achieve the pan-African1 and global goal2 of “Zero Malaria”; and (2) make the compelling case for immunization3 as a set of new tools for malaria control and elimination. | ||
=====A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection===== | |||
[https://www.nature.com/articles/s41541-017-0015-7 by Prakash Srinivasan 22/5/17 npj] | |||
The Plasmodium falciparum protein, apical membrane antigen 1 forms a complex with another parasite protein, rhoptry neck protein 2, to initiate junction formation with the erythrocyte and is essential for merozoite invasion during the blood stage of infection. Consequently, apical membrane antigen 1 has been a target of vaccine development but vaccination with apical membrane antigen 1 alone in controlled human malaria infections failed to protect and showed limited efficacy in field trials. | |||
